Ivermectin Trials Clinical Trials.gov prove the efficacy of Ivermectin
200 Studies either in process of competed for Ivermectin
1. Active, not recruiting
Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19
2. Recruiting
Ivermectin In Treatment of COVID 19 Patients
3. Completed
SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study
Centro Medico Bournigal
Puerto Plata, Dominican Republic
Centro Médico Punta Cana
Punta Cana, Dominican Republic
4. Completed
Ivermectin as a Novel Therapy in COVID-19 Treatment
5. Completed
Has Results
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
6. Completed
Has Results
Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial
Covid-19
Coronavirus Infection
SARS-CoV-2 Infection
Drug: Ivermectin
Drug: Placebo
7. Completed
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19
Hospital de Cuenca Alta
Cañuelas, Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" CEMIC
Buenos Aires, Ciudad De Buenos Aires, Argentina
Hospital de Infecciosas Francisco Javier Muñiz
Ciudad Autonoma de Buenos Aires, Argentina
8. Completed
Has Results
Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
Drug: Ivermectin
Drug: Placebo
9. Recruiting New
Efficacy of Ivermectin in COVID-19
Safety
SARS-CoV2 Infection
Ivermectin Poisoning
Effect of Drug
Drug: Ivermectin
Drug: Placebo
10. Not yet recruiting
The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19
Drug: Ivermectin
Other: Prophylaxis
11. Not yet recruiting
Remdesivir- Ivermectin Combination Therapy in Severe Covid-19
12. Completed
Has Results
Ivermectin and Human Immunity
Drug: Ivermectin
Other: Placebo
13. Recruiting
Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study
14. Completed
Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali
15. Not yet recruiting
Clinical Trial to "Study the Efficacy and Therapeutic Safety of Ivermectin: (SAINTBO)
Drug: Ivermectin
Drug: Placebo
16. Recruiting
Efficacy of Ivermectin in Outpatients With Non-severe COVID-19
Covid19
Coronavirus Infection
Drug: Ivermectin Tablets
Other: Placebo
17. Completed
Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers
18. Completed
Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients
19. Recruiting
Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff
20. Terminated
COVidIVERmectin: Ivermectin for Treatment of Covid-19
Drug: Ivermectin
Other: Placebo
IRCCS Sacro Cuore Don Calabria hospital
Negrar, Verona, Italy
Policlinico S. Orsola
Bologna, Italy
Ospedale Luigi Sacco
Milan, Italy
(and 2 more...)
21. Not yet recruiting
Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
22. Completed
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
23. Enrolling by invitation
Adverse Effects of Ivermectin Used in Egypt During COVID-19
Covid19
Ivermectin Poisoning
Drug Toxicity
Drug Side Effect
24. Recruiting
Ivermectin Treatment Efficacy in Covid-19 High Risk Patients
Sultanah Aminah Hospital
Johor Bahru, Johor, Malaysia
Sultanah Bahiyah Hospital
Alor Setar, Kadah, Malaysia
Sultan Abdul Halim Hospital
Sungai Petani, Kedah, Malaysia
(and 9 more...)
25. Recruiting
Inhaled Ivermectin and COVID-19
26. Completed
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
Ivermectin
Onchocerciasis
Epilepsy
Centre de Recherche en Maladies Tropicales de l'Ituri
Rethy, Ituri, Congo, The Democratic Republic of the
27. Unknown †
Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis
28. Not yet recruiting
Ivermectin Versus Standard Treatment in Mild COVID-19
29. Completed
Has Results
Ivermectin for Severe COVID-19 Management
Afyonkarahisar Health Science University
Afyonkarahisar, Turkey
Gulhane Faculty of Medicine, University of Health Sciences
Ankara, Turkey
Yıldırım Beyazıt University, Ankara City Hospital
Ankara, Turkey
Haydarpasa Sultan Abdulhamid Han Training and Research Hospital
İstanbul, Turkey
30. Recruiting
The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
31. Not yet recruiting
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
32. Completed
Ivermectin to Prevent Hospitalizations in COVID-19
Drug: Ivermectin
Drug: Placebo
33. Completed
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
34. Recruiting
Ivermectin in Treatment of COVID-19
35. Not yet recruiting
Ivermectin Safety in Small Children
Drug: Oral ivermectin
Drug: Permethrin Cream
Other: Placebo tablet
Other: Placebo cream
36. Not yet recruiting
Ivermectin Nasal Spray for COVID19 Patients
Drug: Ivermectin nasal
Drug: Ivermectin oral
Other: standard care
37. Completed
Ivermectin Reproposing for Mild Stage COVID-19 Outpatients
38. Recruiting
Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia
39. Completed
Has Results
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
40. Recruiting
Efficacy of Ivermectin in COVID-19
41. Completed
Has Results
Development of Ivermectin for Alcohol Use Disorders
Drug: Ivermectin
Drug: Placebo
Drug: Alcohol
42. Completed New
Bioequivalence Study to Compare Two Tablets of Ivermectin Tablets (3 mg Ivermectin) Versus Two Tablets of Stromectol ® Tablets (3 mg Ivermectin), in Healthy Subjects Under Fasting Conditions
43. Completed
Has Results
USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19
44. Completed
Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients
45. Completed
Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis
Centro per le Malattie Tropicali, Ospedale Sacro Cuore
Negrar, Verona, Italy
Clinica di Malattie Infettive e Tropicali
Brescia, Italy
UFDID, Azienda Ospedaliero-universitaria Careggi
Florence, Italy
(and 6 more...)
46. Active, not recruiting
Repeat Ivermectin Mass Drug Administrations for MALaria Control II
47. Active, not recruiting
Rosacea and Ivermectin
48. Recruiting
Treatment of Strongyloides Infection
49. Recruiting
Effect of Ivermectin Metabolites on Mosquito Survival
50. Completed
Has Results
Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection
51. Recruiting
Study in Covid-19 Patients With iveRmectin (CORVETTE-01)
Drug: Ivermectin 3 MG
Drug: Placebo
52. Completed
Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy
Centre de Recherche en Maladies Tropicales de l'Ituri
Rethy, Ituri, Congo, The Democratic Republic of the
53. Completed
Ivermectin Solution Bioequivalence Study - With Food (Repeat)
54. Completed
Ivermectin Solution Bioequivalence Study - Fasted
55. Recruiting
Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19
56. Completed
Ivermectin Solution Bioequivalence Study - With Food
57. Not yet recruiting
Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)
58. Withdrawn
Outpatient Use of Ivermectin in COVID-19
Drug: Ivermectin Pill
Drug: Placebo
59. Completed
Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan
60. Completed
A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
Ivermectin
Hydroxychloroquine
COVID19
61. Not yet recruiting
Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]
Drug: Ivermectin
Drug: Placebo
62. Completed
Has Results
Prophylactic Ivermectin in COVID-19 Contacts
63. Recruiting
Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19
Covid19
Coronavirus Infection
SARS-CoV Infection
Drug: Ivermectin
Drug: Placebo
64. Not yet recruiting
The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)
65. Recruiting
Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
Cancer
COVID
Coronavirus Infection
Drug: Placebo
Drug: Ivermectin
Drug: Losartan
66. Withdrawn
Bioavailability Pilot Study of Versus W0035 Versus Stromectol
Drug: ivermectin T1
Drug: ivermectin T2
Drug: ivermectin T3
67. Completed
A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
Drug: Ivermectin Lotion, 0.5%
Drug: SKLICE (ivermectin) Lotion, 0.5%
Drug: Vehicle of the Test product
68. Recruiting
Ivermectin in Adults With Severe COVID-19.
Drug: Ivermectin
Other: Placebo
69. Completed
Has Results
A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
Arkansas Pediatric Clinic
Little Rock, Arkansas, United States
Lice Cleanique, LLC
Delray Beach, Florida, United States
Hill Top Research
St Petersburg, Florida, United States
(and 4 more...)
70. Terminated
A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19
Drug: Ivermectin
Other: Standard of Care
Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar)
São Carlos, São Paulo, Brazil
Hospital Universitário da Universidade Federal de São Carlos (HU-UFSCar)
São Carlos, São Paulo, Brazil
71. Completed
Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
Drug: Moxidectin
Drug: Ivermectin
Centre de Recherche Clinique de Butembo - Université Catholique du Graben
Butembo, Congo, The Democratic Republic of the
Centre de Recherche en Maladies Tropicales de l'Ituri
Rethy, Congo, The Democratic Republic of the
Onchocerciasis Chemotherapy Research Center
Hohoe, Ghana
Liberian Institute for Biomedical Research Clinical Research Center
Bolahun, Lofa County, Liberia
72. Recruiting
Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection
Asymptomatic Infections
SARS-CoV2 Infection
Siriraj Hospital
Bangkok Noi, Bangkok, Thailand
Siriaj Hospital
Bangkok, N/A = Not Applicable, Thailand
Sireethorn Nimitvilai
Amphoe Maueng, Nakhonpathom, Thailand
Golden Jubilee Medical Center
Phutthamonthon District, Nakhonpathom, Thailand
73. Recruiting
Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)
Drug: Ivermectin
Other: Placebo
74. Recruiting
Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis
Drug: Hydroxychloroquine
Drug: Ivermectin
Drug Research and Development Center (NPDM), Federal University of Ceará (UFC)
Fortaleza, Ceará, Brazil
75. Not yet recruiting
Ivermectina Colombia (IVERCOL)
Drug: Ivermectin
Drug: Placebo
76. Completed
Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea
Drug: Soolantra® Ivermectin cream 1%
Drug: Ivermectin cream 1%
Drug: Placebo for Ivermectin cream 1%
Zydus Worldwide DMCC
Brandon, Florida, United States
Zydus Worldwide DMCC
Fort Lauderdale, Florida, United States
Zydus Worldwide DMCC
Miami, Florida, United States
(and 8 more...)
77. Completed
Ivermectin Versus Albendazole for Chronic Strongyloidiasis
Drug: Ivermectin
Drug: ivermectin
Drug: Albendazole
78. Completed
Has Results
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Malaria
Lymphatic Filariasis
Drug: Ivermectin
Drug: Albendazole
Colorado State University
Fort Collins, Colorado, United States
Institut de Recherche en Sciences de la Santé
Bobo Dioulasso, Houet, Burkina Faso
79. Complete
Has Results
Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation
80. Recruiting
Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies
Gale
Severe Forms of Scabies
Oral Parasitic Drug
Ivermectin
81. Not yet recruiting
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
82. Not yet recruiting
Ivermectin and Nitazoxanide Combination Therapy for COVID-19
83. Completed
Has Results
A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation
Drug: Ivermectin Cream
Drug: vehicle control
Cactus Kids Pediatrics
Yuma, Arizona, United States
Universal Biopharma Research, Inc
Dinuba, California, United States
Lice Source Services, Inc.
Plantation, Florida, United States
(and 5 more...)
84. Completed
Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study
85. Recruiting
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
86. Completed
Ivermectin in the Treatment of Head Lice
Drug: ivermectin
Drug: malathion
Hopital Avicenne
Bobigny, Paris, France
Shandon Clinic
Cork, Co. Cork, Ireland
Chaim Sheba Medical Centre
Tel Hashomer, Israel
Synexus Clinical Research Centre
Reading, Berks, United Kingdom
87. Recruiting
An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization
MAX HEALTH, Subsero Health 2055 Wood Street, Suite 100
Sarasota, Florida, United States
88. Unknown †
Efficacy and Safety of Ivermectin Against Dengue Infection
Drug: 2 days Ivermectin
Drug: 3 days Ivermectin
Drug: Placebo
89. Completed
Has Results
Clinical Endpoint Study of Ivermectin 0.5% Lotion
90. Completed
Has Results
Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
Drug: Ivermectin cream
Drug: vehicle control
Cactus Kids Pediatrics
Yuma, Arizona, United States
Impact Clinical Trials
Los Angeles, California, United States
Lice Cleanique, LLC
Delray Beach, Florida, United States
(and 9 more...)
91. Withdrawn
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis
92. Not yet recruiting
Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19
93. Unknown †
Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children
Drug: Ivermectin
Drug: Permethrin
CHU de Bordeaux Hôpital Pellegrin
Bordeaux, Aquitaine, France
CHG de Chalon sur Saône
Chalon sur Saône, Bourgogne, France
CHU de Dijon
Dijon, Bourgogne, France
(and 13 more...)
94. Completed
Ivermectin Role in Covid-19 Clinical Trial
Drug: ivermectin
Drug: hydroxychloroquine
Drug: Placebo
95. Completed
Has Results
Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Drug: Diethylcarbamazine
Drug: Ivermectin
96. Completed
Has Results
Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19
Drug: Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets
Other: Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets
Other: Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.
97. Recruiting
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas
Drug: Moxidectin
Drug: Ivermectin
Centre de Recherche pour les Maladies Tropicales Negligees
Rethy, Ituri, Congo, The Democratic Republic of the
98. Not yet recruiting
Efficacy, Safety and PK of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Drug: Moxidectin 2 mg
Drug: Ivermectin 3 mg
Drug: Placebo
99. Completed
Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic
100. Completed
Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands)
101. Completed
Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%
102. Completed
Has Results
A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age
Children's Investigational Research Program
Bentonville, Arkansas, United States
Universal BioPharma Research, Inc
Dinuba, California, United States
Impact Clinical Trials
Los Angeles, California, United States
(and 2 more...)
103. Completed
Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos
104. Completed
Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial)
105. Not yet recruiting
New Antiviral Drugs for Treatment of COVID-19
106. Completed
Has Results
CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study
Galderma Investigational Site
Pleven, Bulgaria
Galderma Investigational Site
Plovdiv, Bulgaria
Galderma Investigational Site
Sofia, Bulgaria
(and 57 more...)
107. Completed
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
Drug: Diethylcarbamazine
Drug: Albendazole
Drug: Ivermectin
108. Recruiting
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Drug: Moxidectin
Drug: Ivermectin
Centre de Recherche pour les Maladies Tropicales Negligees
Rethy, Ituri, Congo, The Democratic Republic of the
109. Completed
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection
Drug: Hydroxychloroquine
Drug: Ivermectin
Drug: Placebo
110. Completed
Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.
111. Recruiting
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
Coronavirus Infection
COVID
Sars-CoV2
Ali Clinic
Lahore, MA, Pakistan
Shaikh Zayed Hospital
Lahore, Punjab, Pakistan
112. Completed
Has Results
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Drug: Ivermectin
Drug: Azithromycin
Drug: Permethrin
113. Completed
Has Results
Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
Trichuris Infection
Helminthiasis
Drug: Ivermectin
Drug: Albendazole
IIET
Oran, Salta, Argentina
Universidad Autónoma de Honduras
Tegucigalpa, Honduras
114. Completed
Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)
115. Completed
Efficacy and Safety of IVM/ALB Co-administration
Centre Suisse de Recherches Scientifiques en Côte d'Ivoire (CSRS)
Abidjan, Côte D'Ivoire
Lao Tropical and Public Health Institute
Sisattanak, Lao People's Democratic Republic
Public Health Laboratory Ivo de Carneri, P.O. Box 122
Chake Chake, Pemba, Tanzania
116. Enrolling by invitation
Moxidectin for LF, Cote d'Ivoire (DOLF)
Drug: Ivermectin
Drug: Diethylcarbamazine
Drug: Albendazole
Drug: Moxidectin
117. Completed
Has Results
Clinical Endpoint Study of Ivermectin 1% Cream
118. Terminated
Has Results
Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi
Drug: Albendazole 400mg and ivermectin 200mcg/kg
Drug: Albendazole and ivermectin
Drug: albendazole 800mg and ivermectin 400mcg/kg bi-annually
119. Active, not recruiting
Efficacy and Safety of MOX/ALB Co-administration
Trichuriasis
Ascariasis
Hookworm Infections
Drug: Moxidectin 2 mg Oral Tablet
Drug: Albendazole 400 mg Oral Tablet
Drug: Ivermectin 3 mg Oral Tablet
120. Recruiting
Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19
Drug: Ivermectin
Drug: Azithromycin
Drug: Cholecalciferol
121. Not yet recruiting
Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin
Trachoma
Lymphatic Filariases
Drug: Administration of Albendazole on Day 1
Drug: Administration of Ivermectin on Day 1
Drug: Administration of Azithromycin on Day 1
Drug: Administration of Azithromycin on Day 15
122. Completed
Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission
Drug: Artemether-lumefantrine combination
Drug: Artemether-lumefantrine combination + single dose Ivermectin
Drug: Artemether-lumefantrine combination + repeated dose Ivermectin
123. Completed
Treatment of Pediculosis (Head Lice) in Senegal
124. Completed
Twice Yearly Treatment for the Control of LF
Lymphatic Filariasis
Helminth Infection
125. Completed
Has Results
A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
Site 105
Dinuba, California, United States
Site 104
Miami, Florida, United States
Site 101
Plantation, Florida, United States
(and 3 more...)
126. Completed
Ivermectin Neurotoxicity and ABCB1 Gene Mutations
127. Withdrawn
Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients
Onchocerciasis, Ocular
Loiasis
128. Completed
Has Results
Oracea Soolantra Association in Participants With Severe Rosacea
Drug: Ivermectin 1% cream
Drug: Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
Other: Oral placebo capsules
Private Practice
Fort Smith, Arkansas, United States
Private practice
Sacramento, California, United States
Private practice
Boca Raton, Florida, United States
(and 18 more...)
129. Active, not recruiting
Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination
130. Withdrawn
Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
Trachoma
Lymphatic Filariasis
Drug: azithromycin
Drug: ivermectin
Drug: albendazole
Drug: placebo
131. Not yet recruiting
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
Drug: moxidectin (8 mg) / albendazole (400 mg)
Drug: ivermectin (200 µg/kg) / albendazole (400 mg)
Drug: ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]
(and 2 more...)
132. Completed
Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
133. Completed
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
Lymphatic Filariasis
Yaws
Trauma
Drug: Azithromycin
Drug: Albendazole
Drug: Ivermectin
Drug: Diethylcarbamazine
134. Completed
Comparison of the Efficacy and Safety of Ivermectin to Permethrin
135. Enrolling by invitation
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
National Centre for Parasitology, Entomology and Malaria Control
Phnom Penh, Cambodia
National Institute of Public Health
Vientiane, Lao People's Democratic Republic
136. Not yet recruiting
Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients
137. Completed
Veron Scabies Education and Eradication Program
138. Completed
Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections
Ascariasis
Trichuriasis
Hookworm Infection
(and 2 more...)
139. Completed
Has Results
MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
Drug: Brimonidine 0.33% gel (Br)
Other: CD07805/47 (Br) placebo gel
Drug: Ivermectin 1% cream (IVM)
Other: CD5024 (IVM) placebo cream
Fort Smith, Arkansas, United States
Rogers, Arkansas, United States
Sacramento, California, United States
(and 10 more...)
140. Completed
Has Results
Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
141. Recruiting
MANS-NRIZ Trial for COVID-19 Treatment : Extension Study
142. Completed
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
Ivory Coast National Program Against Schistosomiasis, Geohelminths and Filariasis
Abidjan, Lagune-Cocody, Côte D'Ivoire
143. Completed
IVM Alone vs ALB + IVM Against Onchocerciasis
Drug: Ivermectin
Drug: Albendazole
144. Enrolling by invitation
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
145. Unknown †
Management of Soil-transmitted Helminthiasis and Strongyloidiasis
Instituto de Investigación en Enfermedades Tropicales, Universidad Nacional de Salta
Orán, Salta, Argentina
146. Recruiting
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
Drug: Fluvoxamine Maleate 100 MG [Luvox]
Drug: Doxazosin 2 Mg Oral Tablet
Drug: Ivermectin 06 mg Oral Tablet
(and 3 more...)
City of Betim
Betim, MG, Brazil
Hospital e Maternidade Santa Rita
Contagem, MG, Brazil
City of Governador Valadares
Governador Valadares, MG, Brazil
(and 8 more...)
147. Completed
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
Drug: IVM plus ALB
Drug: IVM
148. Completed
Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)
Drug: T1, T2, T3
Drug: T1,T3,T2
Drug: T2,T1,T3
(and 3 more...)
149. Completed
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
Trachoma
Yaws
Lymphatic Filariases
(and 2 more...)
Drug: Albendazole on Day 1
Drug: Ivermectin on Day 1
Drug: Diethylcarbamazine on day 1
(and 2 more...)
150. Completed
Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination
Parasitic Diseases
Bacterial Diseases
151. Completed
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
152. Completed
Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects
Drug Combination
Pharmacokinetics
Healthy
Drug: IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ
Drug: PQ and DHA-PQP and PQ
Drug: DHA-PQP
153. Completed
Safety and Efficacy of Drug Combinations Against Triple Infections
154. Completed
Effect of Albendazole Dose on Clearance of Filarial Worms
Drug: Albendazole
Drug: Ivermectin
155. Completed New
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
156. Completed
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
Drug: 3 drug dose - IDA
Drug: 2 drug dose - DA
Ministere de la Sante Publique et de la Population
Port-au-Prince, Haiti
Vector Control Research Centre
Puducherry, India
Universitas Indonesia
Jakarta, Indonesia
Papua New Guinea Institute for Medical Research
Madang, Papua New Guinea
157. Completed
Lymphatic Filariasis (LF) in Ivory Coast
Drug: Albendazole
Drug: Ivermectin
Drug: Diethylcarbamazine
158. Terminated
Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?
HIV Infections
Helminthiasis
159. Unknown †
Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire
160. Recruiting
Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
Drug: Remdesivir
Drug: Hydroxychloroquine
Drug: Tocilizumab
(and 2 more...)
161. Recruiting
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
Covid19
SARS-CoV Infection
Drug: Metformin
Drug: Placebo
Drug: Fluvoxamine
Drug: Ivermectin
Olive View UCLA Medical Center
Sylmar, California, United States
Anschutz Health and Wellness Center
Aurora, Colorado, United States
New West Physicians
Golden, Colorado, United States
(and 4 more...)
162. Recruiting
Novel Agents for Treatment of High-risk COVID-19 Positive Patients
163. Not yet recruiting
A Phase III Confirmatory Study of K-237
164. Recruiting
Analysis of the Microbiome in Rosacea
Drug: Doxycycline
Drug: Ivermectin Topical
Cutaneous Translational Research Program, Department of Dermatology
Baltimore, Maryland, United States
165. Completed
A Preventive Treatment for Migrant Workers at High-risk of COVID-19
166. Completed
Has Results
Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
167. Enrolling by invitation
Safety and Efficacy of IDA for Onchocerciasis
168. Enrolling by invitation
Tuberculosis - Learning the Impact of Nutrition
Tuberculosis
Malnutrition
Helminth Infection
Dietary Supplement: Nutritional Supplementation Meal
Dietary Supplement: Multivitamin
Drug: Anti-parasitic medications
169. Completed
Epidemiology and Control of Mansonella Perstans Infection in Uganda
Mansonelliasis
Pruritus
Lymphoedema
Abdominal Pains
170. Recruiting
ACTIV-6: COVID-19 Study of Repurposed Medications
Drug: Ivermectin
Drug: Fluvoxamine
Drug: Fluticasone
Other: Placebo
Emory Healthcare
Atlanta, Georgia, United States
NorthShore Medical Group
Evanston, Illinois, United States
Duke Clinical Research Institute
Durham, North Carolina, United States
(and 5 more...)
171. Completed
Safety and Efficacy of Drug Combinations Against Trichuris Trichiura
Drug: albendazole
Drug: mebendazole
Drug: ivermectin
(and 2 more...)
172. Recruiting
Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia
Drug: Ivermectin
Drug: ASP
Drug: Placebo
173. Completed
Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
Drug: Ivermectin
Drug: Placebo
MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence
Manchester, Greater Mancherster, United Kingdom
174. Recruiting
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
Hôpital Général de Référence de Kimpese
Kimpese, Kongo Central, Congo, The Democratic Republic of the
Hôpital Général de Référence de Masi-Manimba
Masi-Manimba, Kwilu, Congo, The Democratic Republic of the
175. Completed
Has Results
Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
176. Completed
Montelukast - a Treatment Choice for COVID-19
Covid19
SARS-CoV-2 Infection
Drug: Montelukast
Drug: Hydroxychloroquine
Drug: Ivermectin
Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Shanghai, China
Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan
Lahore, Punjab, Pakistan
177. Active, not recruiting
Trial of Combination Therapy to Treat COVID-19 Infection
COVID
Covid-19
Corona Virus Infection
(and 4 more...)
Drug: Ivermectin
Drug: Doxycycline Hcl
Dietary Supplement: Zinc
(and 2 more...)
178. Recruiting
Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin)
Drug: InfectoScab 5 % Creme
Drug: Permethrin 10 % Creme
Drug: Driponin 3 mg Tabletten
Uniklinik RWTH Aachen
Aachen, Germany
Universitätsklinikum Augsburg
Augsburg, Germany
Klinikum Darmstadt
Darmstadt, Germany
(and 5 more...)
179. Recruiting
Risk Stratification of COVID-19 Using Urine Biomarkers
MD Mount Sinai
Baltimore, Maryland, United States
Hospital das Clinicas Ribeirao Preto
Ribeirão Preto, San Paulo, Brazil
Danish National Biobank
København, Denmark
(and 4 more...)
180. Recruiting
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
181. Completed
Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
Drug: 2 drug dose - DA
Drug: 3 drug dose - IDA
Ministry of Health and Medical Services
Suva, Fiji
Ministere de la Sante Publique et de la Population
Port-au-Prince, Haiti
Vector Control Research Centre
Puducherry, India
(and 2 more...)
182. Recruiting
Novel Regimens in COVID-19 Treatment
COVID
Corona Virus Infection
Tanta University, Assiut University
Tanta, Egypt
Sherief Abd-Elsalam
Tanta, Egypt
183. Completed
Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis
National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi
Bethesda, Maryland, United States
184. Not yet recruiting
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic
185. Terminated
Effectiveness of Permethrin Impregnated Underwear in Preventing Louse Proliferation in Infected Homeless
186. Not yet recruiting
Evaluation of Strongyloidiasis in Ecuador: a fieLd Laboratory Accuracy Study
187. Recruiting
Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Institut de Recherche pour le Développement
Comé, Benin
Christian Medical College
Vellore, India
London School of Hygiene and Tropical Medicine
Mangochi, Malawi
188. Unknown †
Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012
Drug: Pyridoxine
Drug: Sodium Valproate
Drug: Phenytoin
Drug: Placebo
189. Completed
Prevalence of LF Infection in Districts Not Included in LF Control Activities
Lymphatic Filariases
Onchocerciasis
Diagnostic Test: Diagnosis of lymphatic filariasis
Diagnostic Test: Diagnosis of lymphatic Filariasis and onchocerciasis
Diagnostic Test: DEC Patch
190. Completed
Study of Patients With Strongyloides Stercoralis Infection
HIV Infection
Nematode Infection
Strongyloidiasis
191. Recruiting
East New Britain Province Monitoring & Evaluation
Lymphatic Filariasis Elimination by Mass Drug Administration
Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
Acceptability of Mass Drug Administration for Lymphatic Filariasis
192. Recruiting
Host Response to Infection and Treatment in Filarial Diseases
Filariasis
Helminthiasis
Parasitic Infection
(and 2 more...)
193. Completed
The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands
Flavivirus Infection
Alphavirus Infections
Malaria
(and 4 more...)
194. Unknown †
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
Nodding Syndrome
Epilepsy
Onchocerciasis
Cognitive Impairment
195. Recruiting
Safety, Tolerability, and Pharmacokinetics of EQU-001 in Healthy Volunteers
Drug: EQU-001
Drug: Placebo
196. Completed
Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
Lung Cancer
Smoking
Radiation Exposure
197. Completed
Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis
198. Completed
The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients
Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine
Seoul, Korea, Republic of
199. Recruiting
Clinical Evaluation of a New Form of Cancer Therapy Based on the Principles of Atavistic Metamorphosis (Atavistic Chemotherapy).
Dr. Frank Arguello Cancer Clinic
San Jose del Cabo, Baja California Sur, Mexico
Instituto de Ciencia y Medicina Genomica
Torreon, Coahuila, Mexico
200. Completed
Host Response to Infection and Treatment in Lymphatic Filarial Disease in India
In my judgment we have made the case for ivermectin based on science. The data is there and when you compare the counter argument from the government and big Pharm it is at best vacuous failing to admit both the documented success and safety of this drug. I may have failed to substantially document the motives that we must attribute to the US Government, the Talking heads, and big Pharm. Look to Mexico and India and the data cited below on what happened after ivermectin was introduced to COVID positive patients. The medical community knows this, big Pharm knows this, the government knows this… CNN and MSNBC probably don’t, given their limited affinity for journalism. Point being.. trashing ivermectin is purposeful and we must all do our own research to make our medical decisions…. regardless of our political persuasion COVID pretty much attacks without checking. And think about this if the case for ivermectin was baseless would the argument against be censorship or a robust scientific debate. If you can’t win the argument, you , limit the facts to the public, discredit the opposing experts, and scare the crap out of everybody. Sound familiar? We live in scary times.
After Mexico City introduced ivermectin plan, COVID hospitalizations and deaths disappeared
An initiative in Mexico City to prescribe ivermectin to COVID-19 positive patients has resulted in a 52–76 percent reduction in hospitalizations.
IvermectinShutterstock
Wed May 26, 2021 - 5:10 pm EDT
MEXICO CITY, May 26, 2021 (LifeSiteNews) — A city-wide initiative in Mexico’s bustling capital to prescribe ivermectin to COVID-19 positive patients has resulted in a 52–76 percent reduction in hospitalizations, according to research by the Mexican Digital Agency for Public Innovation (DAPI), Mexico’s Ministry of Health, and the Mexican Social Security Institute (IMSS).
Concerned about hospital capacity in the summer of 2020, the Mexican government devised an aggressive testing regime, ramping up from 3,000 tests per day in June to around 24,000 antigen tests every day by that November, according to TrialSiteNews. Mexico City Ministry of Health head Oliva López later announced that doctors will give ivermectin and azithromycin to treat COVID-19.
“The Ministry of Health has identified that there is enough evidence to use in people positive for SARS-CoV-2, even without symptoms, some drugs such as ivermectin and azithromycin,” López confirmed in a press conference.
Local authorities created a home-treatment-kit, including ivermectin, for its 22 million-strong population on December 28, 2020, following a spike in cases of COVID-19.
Individuals testing positive for COVID from an antigen test, and who were experiencing at least mild symptoms, began receiving one of the government’s ivermectin-based treatment kits from December 29.
As part of the program of testing and early treatment, the Mexican government opened a study to track the effect that early treatment of COVID with ivermectin was having on the city’s population. Run by the Mexico Ministry of Health, DAPI, and IMSS, a phone-based monitoring program traced the health of individuals testing positive for COVID with an antigen test. The study followed two cohorts — those who received ivermectin and those who did not — and included 200,000 people, TrialSiteNews revealed.
Using the data garnered from its phone-call-based monitoring system and hospital data on admissions for COVID-19, the researchers discovered a significant reduction in hospitalizations for the group administered ivermectin versus the group which was not, totaling between 52 percent and 76 percent effective at preventing hospitalization.
Dr. Juan J. Chamie-Quintero, a senior data analyst at private Colombian university EAFIT, followed the trends in hospitalizations and deaths in Mexico City before and after the government implemented its ivermectin treatment program.
Chamie-Quintero’s findings corroborated the Mexican government’s observations. The charts below, posted to Chamie-Quintero’s Twitter page, show COVID hospitalizations and deaths both peaking around the middle of January 2021, about two weeks after ivermectin started being distributed on December 29.
COVID-19 in Mexico
Since December 29 Mexico City started using ivermectin treatment in COVID-19 positive patients. Up to Jan 22 2020 they had delivered more than 50,000 treatments.
Update (data up to Feb 6 2020 – charts up to Jan 31) pic.twitter.com/xyEfQP4XQE pic.twitter.com/T1Iy9UHjaR
— J Chamie (@jjchamie) February 7, 2021
In the month following, over 50,000 treatments had been delivered, coinciding with a steep drop in the number of both hospitalizations and deaths involving COVID-19 in Mexico City.
https://www.citizensjournal.us/covid-deaths-plunge-after-major-world-city-introduces-ivermectin/
COVID deaths plunge after major world city introduces ivermectin
Authorities create home-treatment-kit for 22 million-strong population
A citywide initiative in Mexico City to prescribe ivermectin to COVID-19 patients resulted in a plunge in hospitalizations and deaths, two studies found.
Hospitalizations were down by as much as 76%, according to research by the Mexican Digital Agency for Public Innovation, Mexico’s Ministry of Health and the Mexican Social Security Institute, according to a TrialSiteNews report highlighted by LifeSiteNews.
Earlier this month, as WND reported, a significant decrease in cases in India coincided with the national health ministry’s promotion of ivermectin and hydroxychloroquine treatments.
In Mexico City, after a spike in cases in December, the city’s Ministry of Health created a home-treatment kit for residents. The city’s metro population is 22 million.
At the time, the head of the Mexico City Ministry of Health, Oliva López, said told reporters her agency had determined “that there is enough evidence to use in people positive for SARS-CoV-2, even without symptoms, some drugs such as ivermectin and azithromycin.”
Beginning Dec. 29, people who tested positive for COVID from an antigen test and who were experiencing at least mild symptoms began receiving one of the government’s ivermectin-based treatment kits, TrialSiteNews reported.
The Mexican government then began a study to track the impact of the early treatment of COVID with ivermectin on the city’s population.
The study tracked 200,000 people, dividing in two cohorts — those who received ivermectin and those who did not.
Are governments preventing the public from getting treatments that actually help defeat COVID?
Through a phone-call-based monitoring system and hospital data on admissions for COVID-19, the researchers found a reduction of between 52% and 76% in hospitalizations for those who took ivermectin compared to those who did not.
The government’s findings were corroborated by Dr. Juan J. Chamie-Quintero, a senior data analyst at private Colombian university EAFIT.
He found that excess deaths in the city dropped sharply only a few weeks after the ivermectin treatments began.
Chamie-Quintero also conducted a study in Peru, where the government approved ivermectin as a treatment for the virus in May 2020.
In the 24 Peruvian states that adopted early use of ivermectin treatment, excess deaths plummeted on average by 59% just 30 days after the peak death rate. And it had dropped 75% after 45 days in those over 60 years old.
‘Large, statistically significant reductions in mortality’
Worldwide, more than 50 peer-reviewed studies have shown the effectiveness of ivermectin as a treatment and prophylaxis against COVID-19.
A study by the American Journal of Therapeutics that analyzed 18 randomized controlled treatment trials found ivermectin elicited “large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance” in COVID patients.
The study concluded that “the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.”
In February, a peer-reviewed study found that invermectin reduces coronavirus infections, hospitalizations and deaths by about 75%.
Ivermectin, in more than 30 trials around the world, causes “repeated, consistent, large magnitude improvements in clinical outcomes’ at all stages of the disease,” according to the study, which was published in the U.S. journal Frontiers of Pharmacology.
The evidence is so strong, the researchers believe, the anti-parasitic drug should become a standard therapy everywhere, hastening global recovery.
“The data is overwhelming – we are in a pandemic, and this is an incredibly effective way to combat it. If we use ivermectin widely, our societies can open up,” said study co-author Professor Paul Marik, director of emergency and pulmonary care at Eastern Virginia Medical School.
A previous study by Professor Andrew Hill of Liverpool University also found ivermectin cuts death rates by about 75%.
‘Inaction in front of mounting evidence’
Dr. Pierre Kory, the chief medical officer of the Front Line Covid-19 Critical Care Alliance, is known for his congressional testimony about the effectiveness of ivermectin. In a live Zoom conference May 13, he showed the promising data from various states in India in the two weeks after ivermectin was promoted.
https://newsrescue.com/the-undeniable-ivermectin-miracle-indias-240m-populated-largest-state-uttar-pradesh-horowitz/
The Undeniable Ivermectin Miracle in India’s 240m Populated Largest State, Uttar Pradesh – Horowitz - NewsRescue.com
Uttar Pradesh might sound obscure to most Americans, but it is the most populated state in India, with urban areas that rival the most densely populated cities in the U.S. Yet, miraculously, despite housing a population of 240 million people, this northern state has been averaging only 24 cases.
Last year, the northern state of Uttar Pradesh began dispensing ivermectin liberally and encouraging people to take it early on and even preventively. As Trial Site News reported earlier this year, “By the end of 2020, Uttar Pradesh — which distributed free ivermectin for home care — had the second-lowest fatality rate in India at 0.26 per 100,000 residents in December. Only the state of Bihar, with 128 million residents, was lower, and it, too, recommends ivermectin.”Don’t miss out on content from Dave Rubin free of big tech censorship. Listen to The Rubin Report now.
As you can see, COVID has been dead in Uttar Pradesh with the exception of a very brief six-week spike in the early spring. Uttar Pradesh likely would have been the first world experiment of what a given area would have looked like had they been taking ivermectin from day one before a wave hit. Unfortunately, hundreds of thousands of seasonal migrants fled Mumbai and other big cities when the Delta wave hit and all settled back in their villages in Uttar Pradesh, giving them the same spike that every other state got because those people were not on ivermectin. As the AP reported in mid-April, during the surge in Uttar Pradesh, many of these seasonal workers who work half the year in the big cities returned home to their villages. They were likely not taking ivermectin.
But when the state began distributing the drug to everyone, cases plummeted quicker and sharper than anywhere else we’ve seen in the world, and the gains have held for months with record low cases. Dr. Surya Kant Tripathi, head of the Respiratory Medicine Department, King George Medical University, Lucknow, told the Financial Express Online in April that the state began giving ivermectin to everyone who was in home isolation (rather than telling them to do nothing until they can’t breathe, like we do here in the United States).
They also avoided use of the odious remdesivir. “All trials are saying that this drug is not effective in the treatment of COVID-19, rather it is complicating and resulting in mortality of patients,” said Dr. Tripathi. “At so many centers, remdesivir trials were stopped. Also, remdesivir is costing minimum of Rs 5,000 per vial.”
Overall, the death rate in Uttar Pradesh was roughly 95 per million people, roughly 1/20 the death rate of the U.S. More importantly, despite being the largest state in India, it incurred one-third the death rate of the country as a whole.
Take a look at this comparison between the death curve in Uttar Pradesh and the curve in India at large:
You will see that Uttar Pradesh experienced a plummeting of deaths more precipitous than India in the aggregate. Moreover, while cases and deaths in recent months have generally been pretty low in India because most people already got the virus, the pandemic is completely dead in Uttar Pradesh.
MSN: Uttar Pradesh government says early use of Ivermectin helped to keep positivity, deaths low
To put this comparison in another perspective, it took from May 9 to June 23 (45 days) for cases to decline 86% off the peak seven-day average for India at large. Not only did Uttar Pradesh peak earlier (April 27), it took just 30 days for it to achieve an 86% drop. By the 45-day window of comparison, cases in Uttar Pradesh had already dropped 98%. Today, it stands at 99.93% off the peak!
Now let’s compare this to the state of Kerala, which has removed ivermectin and other proven therapeutics from its treatment protocol and has gone all in on the ineffective remdesivir. Not only have cases not declined, but they have gone backward.
Remember, Kerala, at 34 million people, is just a fraction of the size of Uttar Pradesh.
Furthermore, just 4.5% of people in Uttar Pradesh are fully vaccinated, compared to 20% in Kerala. In this tiny state, already 70% of people 45 years and older and almost 56% of its population have had at least one shot.
Some might suggest that Kerala, being a southern state, is not a good comparison to the northern state of Uttar Pradesh because it is likely on a different epidemiological schedule. However, while Uttar Pradesh was the first state to use ivermectin, others have followed suit. Goa, which is a southern state, began offering ivermectin to all adults on May 11 and experienced a remarkable and durable decline.
Delhi, Karnataka, and Uttarakhand also used ivermectin widely and have basically eradicated the virus.
Thus, if anything, if we are to believe a government can force people to inject medicine into their bodies to stop the virus, governments everywhere would be following the science by a factor of 100 were they to mandate ivermectin rather than the vaccines. Everyone now agrees the vaccines do not stop transmission. The only question is how long the efficacy against serious illness lasts, for whom, and whether it broadly creates antibody dependent disease enhancement.https://playlist.megaphone.fm/?e=BMDC2861655210
We already have dozens of studies vouching for the efficacy of ivermectin. While the establishment likes to complain about the sample size of each one individually, as one study published in Nature noted, “The probability that an ineffective treatment generated results as positive for the 55 studies to date is estimated to be 1 in 23 trillion (p = 0.000000000000043).” The story of Uttar Pradesh and the other Indian states that used ivermectin certainly demonstrates this.
Ivermectin was regarded as a “wonder drug” responsible for virtually eradicating river blindness in Africa. Given its robust anti-viral and anti-inflammatory mechanisms of action, Uttar Pradesh is a living testament that it could have been used to wipe COVID off the map as well. Sadly, the Western world would rather bankrupt us and cause more deaths for politically driven solutions that don’t work than cede back to the people the control they’ve established. Perhaps there is a lot we can learn from the third world, for we are now seeing the growth of a “fourth world” mentality that is much more destructive than the third world.